Biomarker Insights最新文献_第8页

Effect of Methylprednisolone on Inflammation and Coagulation in Patients with Severe COVID-19: A Retrospective Cohort Study. 甲泼尼龙对重症COVID-19患者炎症和凝血的影响:一项回顾性队列研究

IF 3.8

Biomarker Insights Pub Date : 2021-06-04 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211021647

Katja Tromp, Philip van der Zee, Casper Rokx, Jeroen van Kampen, Diederik Gommers, Henrik Endeman

引用次数: 2

Extracellular Vesicle Proteome of Breast Cancer Patients with and Without Cognitive Impairment Following Anthracycline-based Chemotherapy: An Exploratory Study. 蒽环类药物化疗后认知障碍的乳腺癌患者的细胞外囊泡蛋白质组:一项探索性研究

IF 3.8

Biomarker Insights Pub Date : 2021-05-24 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211018204

Yong Qin Koh, Ding Quan Ng, Chiu Chin Ng, Adrian Boey, Meng Wei, Siu Kwan Sze, Han Kiat Ho, Munjal Acharya, Charles L Limoli, Alexandre Chan

{"title":"Extracellular Vesicle Proteome of Breast Cancer Patients with and Without Cognitive Impairment Following Anthracycline-based Chemotherapy: An Exploratory Study.","authors":"Yong Qin Koh, Ding Quan Ng, Chiu Chin Ng, Adrian Boey, Meng Wei, Siu Kwan Sze, Han Kiat Ho, Munjal Acharya, Charles L Limoli, Alexandre Chan","doi":"10.1177/11772719211018204","DOIUrl":"https://doi.org/10.1177/11772719211018204","url":null,"abstract":"Cognitive impairment due to cancer and its therapy is a major concern among cancer patients and survivors. Extracellular vesicle (EVs) composition altered by cancer and chemotherapy may affect neurological processes such as neuroplasticity, potentially impacting the cognitive abilities of cancer patients and survivors. We investigated the EV proteome of breast cancer patients with and without cognitive impairment following anthracycline-based chemotherapy from longitudinally collected plasma. EVs were cup-shaped and positive for Flotillin-1 and TSG-101. We identified 517 differentially expressed EV proteins between the cognitive impaired and non-impaired groups during and post-chemotherapy. The observed decreased expression of p2X purinoceptor, cofilin-1, ADAM 10, and dynamin-1 in the plasma EVs of the cognitive impaired group may suggest alterations in the mechanisms underlying synaptic plasticity. The reduced expression of tight junction proteins among cognitive-impaired patients may imply weakening of the blood-brain barrier. These EV protein signatures may serve as a fingerprint that underscores the mechanisms underlying cognitive impairment in cancer patients and survivors.","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2021-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/11772719211018204","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38995358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

IL-6 and Other Biomarkers associated with Poor Prognosis in a Cohort of Hospitalized Patients with COVID-19 in Madrid. 马德里一项与COVID-19住院患者预后不良相关的IL-6和其他生物标志物

IF 3.8

Biomarker Insights Pub Date : 2021-05-24 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211013363

Encarnación Donoso-Navarro, Ignacio Arribas Gómez, Francisco A Bernabeu-Andreu

{"title":"IL-6 and Other Biomarkers associated with Poor Prognosis in a Cohort of Hospitalized Patients with COVID-19 in Madrid.","authors":"Encarnación Donoso-Navarro, Ignacio Arribas Gómez, Francisco A Bernabeu-Andreu","doi":"10.1177/11772719211013363","DOIUrl":"https://doi.org/10.1177/11772719211013363","url":null,"abstract":"Objectives: There are several published works on the prognostic value of biomarkers in relation to the severity or fatal outcome of coronavirus disease 2019 (COVID-19). In Spain, the second European country in incidence of the disease at the time of data collection, there are few studies that include both laboratory parameters and clinical parameters. Our aim is to study the relationship of a wide series of biomarkers with admission to intensive care and death in a hospital in the Autonomous Community of Madrid (Spain), with special attention to IL-6 due to its role in the systemic inflammatory response associated with a worse prognosis of the disease. Methods: Data were collected from 546 hospitalized patients with COVID-19. All of them had IL-6 results, in addition to other biochemical and haematological parameters. The difference of the medians for the selected parameters between the groups (ICU vs non-ICU, dead vs survivors) was studied using a Mann-Whitney analysis. The independent variables that predicted death were studied using a Cox proportional hazard regression model. Results: Higher age and blood concentrations of ALT, creatinine, CK, cTnI, LDH, NT-proBNP, CRP, IL-6, leucocyte count and D-dimer together with lower blood concentrations of albumin and lymphocyte count were associated with mortality in univariate analysis. Age, LDH, IL-6 and lymphocyte count remained associated with death in multivariate analysis. Conclusions: Age, LDH, IL-6 and lymphocyte count, as independent predictors of death, could be used to establish more aggressive therapies in COVID-19 patients.","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2021-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/11772719211013363","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38995357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Circadian, Week-to-Week, and Physical Exercise-Induced Variation of Serum Microfibrillar-Associated Protein 4. 血清微纤维相关蛋白的昼夜、周与周和体育锻炼引起的变化

IF 3.8

Biomarker Insights Pub Date : 2021-05-14 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211016359

Susanne Gjørup Sækmose, René Holst, Tine Lottenburger, Henriette Ytting, Hans Jørgen Nielsen, Peter Junker, Anders Schlosser, Grith Lykke Sorensen

{"title":"Circadian, Week-to-Week, and Physical Exercise-Induced Variation of Serum Microfibrillar-Associated Protein 4.","authors":"Susanne Gjørup Sækmose, René Holst, Tine Lottenburger, Henriette Ytting, Hans Jørgen Nielsen, Peter Junker, Anders Schlosser, Grith Lykke Sorensen","doi":"10.1177/11772719211016359","DOIUrl":"https://doi.org/10.1177/11772719211016359","url":null,"abstract":"Serum microfibrillar-associated protein 4 (sMFAP4) has been investigated as a biomarker for various diseases and is demonstrated to show significant gradual increase with severity of liver fibrosis. Ideal biomarkers used for disease diagnosis or prognosis should display deviating levels in affected individuals only and be robust to factors unrelated to the disease. Here we show the impact of normal physiological variation of sMFAP4 by characterizing the circadian variation, week-to-week variation, and physical exercise-induced levels. Serum samples from 3 groups of healthy volunteers were drawn: 7 times during a 24-hour period, 5 times during a 3-week period, and before and after a standardized physical exercise challenge. sMFAP4 was determined by AlphaLISA. Statistical analysis was performed using mixed effects modeling of repeated measurements. Circadian variation of sMFAP4 was demonstrated, with time of peak and nadir values depending on age and gender. For males, the peak values were observed during nighttime whereas for females, peak values were observed in the morning. Individual sMFAP4 levels remained stable over a period of 3 weeks and physical exercise inferred a mild negative influence. In conclusion, the circadian sMFAP4 variation was significant, and the levels could be influenced by physical activity. However, these variations were of limited magnitude relative to previously observed disease-induced levels in support of the biomarker potential of sMFAP4.","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2021-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/11772719211016359","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38936847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Multiple Sclerosis Biomarker Discoveries by Proteomics and Metabolomics Approaches. 通过蛋白质组学和代谢组学方法发现多发性硬化症生物标志物。

IF 3.8

Biomarker Insights Pub Date : 2021-05-06 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211013352

Ameneh Jafari, Amirhesam Babajani, Mostafa Rezaei-Tavirani

{"title":"Multiple Sclerosis Biomarker Discoveries by Proteomics and Metabolomics Approaches.","authors":"Ameneh Jafari, Amirhesam Babajani, Mostafa Rezaei-Tavirani","doi":"10.1177/11772719211013352","DOIUrl":"10.1177/11772719211013352","url":null,"abstract":"Multiple sclerosis (MS) is an autoimmune inflammatory disorder of the central nervous system (CNS) resulting in demyelination and axonal loss in the brain and spinal cord. The precise pathogenesis and etiology of this complex disease are still a mystery. Despite many studies that have been aimed to identify biomarkers, no protein marker has yet been approved for MS. There is urgently needed for biomarkers, which could clarify pathology, monitor disease progression, response to treatment, and prognosis in MS. Proteomics and metabolomics analysis are powerful tools to identify putative and novel candidate biomarkers. Different human compartments analysis using proteomics, metabolomics, and bioinformatics approaches has generated new information for further clarification of MS pathology, elucidating the mechanisms of the disease, finding new targets, and monitoring treatment response. Overall, omics approaches can develop different therapeutic and diagnostic aspects of complex disorders such as multiple sclerosis, from biomarker discovery to personalized medicine.","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2021-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ba/e8/10.1177_11772719211013352.PMC8114757.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38933381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mind Over Matter: Confronting Challenges in Post-Mortem Brain Biobanking for Glioblastoma Multiforme. 精神高于物质:多形性胶质母细胞瘤死后脑生物银行面临的挑战。

IF 3.8

Biomarker Insights Pub Date : 2021-04-30 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211013359

Cassandra Griffin, Ricardo Vilain, Simon King, Sandy Nixon, Alisha Gooley, Samara Bray, James Lynam, Marjorie M Walker, Rodney J Scott, Christine Paul

{"title":"Mind Over Matter: Confronting Challenges in Post-Mortem Brain Biobanking for Glioblastoma Multiforme.","authors":"Cassandra Griffin, Ricardo Vilain, Simon King, Sandy Nixon, Alisha Gooley, Samara Bray, James Lynam, Marjorie M Walker, Rodney J Scott, Christine Paul","doi":"10.1177/11772719211013359","DOIUrl":"https://doi.org/10.1177/11772719211013359","url":null,"abstract":"Over the past 10 years, there has been limited progress for the treatment of brain cancer and outcomes for patients are not much improved. For brain cancer researchers, a major obstacle to biomarker driven research is limited access to brain cancer tissue for research purposes. The Mark Hughes Foundation Brain Biobank is one of the first post-mortem adult brain banks in Australia to operate with protocols specifically developed for brain cancer. Located within the Hunter New England Local Health District and operated by Hunter Cancer Biobank, the boundaries of service provided by the Brain Bank extend well into the surrounding regional and rural areas of the Local Health District and beyond. Brain cancer biobanking is challenging. There are conflicting international guidelines for best practice and unanswered questions relating to scientific, psychosocial and operational practices. To address this challenge, a best practice model was developed, informed by a consensus of existing data but with consideration of the difficulties associated with operating in regional or resource poor settings. The regional application of this model was challenged following the presentation of a donor located in a remote area, 380km away from the biobank. This required biobank staff to overcome numerous obstacles including long distance patient transport, lack of palliative care staff, death in the home and limited rural outreach services. Through the establishment of shared goals, contingency planning and the development of an informal infrastructure, the donation was facilitated within the required timeframe. This experience demonstrates the importance of collaboration and networking to overcome resource insufficiency and geographical challenges in rural cancer research programmes.","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2021-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/11772719211013359","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39930049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Quality Considerations When Using Tissue Samples for Biomarker Studies in Cancer Research. 在癌症研究中使用组织样本进行生物标记物研究时的质量考虑因素。

IF 3.8

Biomarker Insights Pub Date : 2021-04-20 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211009513

Valerie Speirs

引用次数: 0

The Assessment of the Usefulness of Selected Markers in the Diagnosis of Chronic Kidney Disease in Children. 评估选定标记物在诊断儿童慢性肾脏病中的实用性。

IF 3.8

Biomarker Insights Pub Date : 2021-04-20 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211011173

Agata Będzichowska, Katarzyna Jobs, Małgorzata Kloc, Anna Bujnowska, Bolesław Kalicki

{"title":"The Assessment of the Usefulness of Selected Markers in the Diagnosis of Chronic Kidney Disease in Children.","authors":"Agata Będzichowska, Katarzyna Jobs, Małgorzata Kloc, Anna Bujnowska, Bolesław Kalicki","doi":"10.1177/11772719211011173","DOIUrl":"10.1177/11772719211011173","url":null,"abstract":"Introduction: The kidney deterioration, which starts in childhood often leads to end-stage renal failure in the future. Therefore, searching for an early, sensitive, and specific biomarkers became a paramount for chronic kidney disease diagnosis. The aim of this study was the assessment of markers: KIM-1, FGF-23, NAG, NGAL, and uromodulin for diagnosis of preclinical phase of the disease in children.Patients and methods: 59 children (15 boys, 44 girls from 6 months to 17 years old) with kidney disorders, which had clinical indications for renoscintigraphy, were included in the study. All patients were divided depending on the result of renoscintigraphy (renal scarring vs normal kidney picture) and depending on the level of estimated glomerular filtration rate (glomerular hyperfiltration vs normal filtration rate). The concentration of uromoduline, KIM-1, FGF-23, NAG, and NGAL in serum and of NGAL and uromoduline in urine were measured in all studied groups.Results: The children with glomerular hyperfiltration had a statistically significantly higher serum values of FGF-23 and NGAL than the children with normal filtration rate (P < .05). There were no statistically significant differences in serum concentrations of tested markers in children with renal scars in comparison to children with normal renal image. There was no statistically significant difference in the concentration of tested markers in urine.Conclusions: The study confirmed the possible usefulness of FGF-23 and NGAL in detecting the preclinical-stage of renal disease associated with glomerular hyperfiltration in children. The study do not allow to indicate markers, which could be useful in the early diagnosis of kidney damage visible in the scintigraphic examination.","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2021-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/41/13/10.1177_11772719211011173.PMC8060753.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38877425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cytokine Profiling in Plasma from Patients with Brain Tumors Versus Healthy Individuals using 2 Different Multiplex Immunoassay Platforms. 使用两种不同的多重免疫分析平台分析脑肿瘤患者与健康人血浆中的细胞因子谱

IF 3.8

Biomarker Insights Pub Date : 2021-03-30 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211006666

Diane Elizabeth Bender, Maximilian O Schaettler, Kathleen Cf Sheehan, Tanner M Johanns, Gavin P Dunn

{"title":"Cytokine Profiling in Plasma from Patients with Brain Tumors Versus Healthy Individuals using 2 Different Multiplex Immunoassay Platforms.","authors":"Diane Elizabeth Bender, Maximilian O Schaettler, Kathleen Cf Sheehan, Tanner M Johanns, Gavin P Dunn","doi":"10.1177/11772719211006666","DOIUrl":"https://doi.org/10.1177/11772719211006666","url":null,"abstract":"We compared the performance of two 96-well multiplex immunoassay platforms in assessing plasma cytokine concentrations in patients with glioblastoma (GBM; n = 27), individuals with melanoma, breast or lung cancer metastases to the brain (n = 17), and healthy volunteers (n = 11). Assays included a bead-based fluorescence MILLIPLEX® assay/Luminex (LMX) platform and 4 planar electrochemiluminescence kits from Meso Scale Discovery (MSD). The LMX kit evaluated 21 cytokines and the 3 MSD kits evaluated 20 cytokines in total, with 19 overlapping human cytokines between platforms (GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-21, IL-23, MIP-1α, MIP-1β, MIP-3α, TNFα). The MSD platform had lower LLoQs (lower limits of quantification) than LMX for 17/19 cytokines, and higher LLoQs for IFN-γ and IL-21. The ULoQs were higher in LMX versus MSD assays for 17/19 shared analytes, but lower than MSD for IL-17A and IL-21. With LMX, all 19 shared analytes were quantifiable in each of 55 samples. Although MSD recombinant protein standard curves indicated lower LLoQs than LMX for most cytokines, MSD detected 7/19 (37%) native analytes in <75% of samples, including 0% detection for IL-21 and 8% for IL-23. The LMX platform categorized identical samples at greater concentrations than the MSD system for most analytes (MIP-1β the sole exception), sometimes by orders of magnitude. This mismatched quantification paradigm was supported by Bland-Altman analysis. LMX identified significantly elevated levels of 10 of 19 circulating cytokines in GBM: GM-CSF, IFN-γ, IL-1β, IL-5, IL-10, IL-17A, IL-21, IL-23, MIP-1α, and MIP-3α, consistent with prior findings and confirming the utility of applying appropriate multiplex immunoassay technologies toward developing a cytokine signature profile for GBM.","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2021-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/11772719211006666","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25591522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Moving with the Times: The Health Science Alliance (HSA) Biobank, Pathway to Sustainability. 与时俱进:健康科学联盟(HSA)生物库，可持续发展之路。

IF 3.8

Biomarker Insights Pub Date : 2021-03-27 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211005745

Carmel M Quinn, Mamta Porwal, Nicola S Meagher, Anusha Hettiaratchi, Carl Power, Jitendra Jonnaggadala, Sue McCullough, Stephanie Macmillan, Katrina Tang, Winston Liauw, David Goldstein, Nikolajs Zeps, Philip J Crowe

{"title":"Moving with the Times: The Health Science Alliance (HSA) Biobank, Pathway to Sustainability.","authors":"Carmel M Quinn, Mamta Porwal, Nicola S Meagher, Anusha Hettiaratchi, Carl Power, Jitendra Jonnaggadala, Sue McCullough, Stephanie Macmillan, Katrina Tang, Winston Liauw, David Goldstein, Nikolajs Zeps, Philip J Crowe","doi":"10.1177/11772719211005745","DOIUrl":"https://doi.org/10.1177/11772719211005745","url":null,"abstract":"Human biobanks are recognised as vital components of translational research infrastructure. With the growth in personalised and precision medicine, and the associated expansion of biomarkers and novel therapeutics under development, it is critical that researchers can access a strong collection of patient biospecimens, annotated with clinical data. Biobanks globally are undertaking transformation of their operating models in response to changing research needs; transition from a 'classic' model representing a largely retrospective collection of pre-defined specimens to a more targeted, prospective collection model, although there remains a research need for both models to co-exist. Here we introduce the Health Science Alliance (HSA) Biobank, established in 2012 as a classic biobank, now transitioning to a hybrid operational model. Some of the past and current challenges encountered are discussed including clinical annotation, specimen utilisation and biobank sustainability, along with the measures the HSA Biobank is taking to address these challenges. We describe new directions being explored, going beyond traditional specimen collection into areas involving bioimages, microbiota and live cell culture. The HSA Biobank is working in collaboration with clinicians, pathologists and researchers, piloting a sustainable, robust platform with the potential to integrate future needs.","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2021-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/11772719211005745","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39930047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8